US Bioservices is now dispensing Novartis’ KISQALI®
3/16/17 The U.S Food and Drug Administration recently approved Novartis’ KISQALI®(ribociclib) for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer. Continue reading now.
US Bioservices selected by AstraZeneca to dispense IRESSA and TAGRISSO
2/6/17 US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today it has been selected by AstraZeneca to dispense IRESSA® (gefitinib) and TAGRISSO® (osimertinib) for the treatment of advanced non-small cell lung cancer in patients whose tumors foster gene mutations.Continue reading now.
US Bioservices has once-daily VIEKIRA XR® in stock
8/3/2016 VIEKIRA XR® was approved by the U.S. Food and Drug Administration on July 25, 2016 as a once-daily, extended-release co-formulation of the active ingredients in VIEKIRA XR (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and is for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis (Child-Pugh A). VIEKIRA XR is not for people with decompensated cirrhosis. Continue reading now.
US Bioservices has Pfizer’s XALKORI® in stock – now FDA approved to treat metastatic non-small cell lung cancer
7/11/2016 The U.S. Food and Drug Administration recently approved the expanded use of Pfizer’s XALKORI® (crizotinib) for the treatment of metastatic non-small cell lung cancer (NSCLC), when tumors have an ROS-1 gene alteration. The FDA also granted XALKORI® breakthrough therapy designation and priority review status. Continue reading now.
US Bioservices has Genentech’s XOLAIR® in stock
7/5/2016 US Bioservices has been selected as an authorized specialty pharmacy in a limited distribution network for XOLAIR® (omalizumab). Xolair is an anti-IgE antibody subcutaneous injection medication with two therapeutic indications.Continue reading now.
US Bioservices Dispensing Gilead’s EPCLUSA® for All Genotypes of HCV
6/28/2016 The U.S. Food and Drug Administration recently approved Gilead’s EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg), the first oral single tablet regimen for the treatment of adults with genotypes 1-6 chronic hepatitis C virus (HCV) infection. Continue reading now.
US Bioservices is Dispensing TETRABENAZINE, generic therapy for Huntington’s chorea
3/31/2016 Through a partnership with Kadmon Pharmaceuticals, LLC, and Camber Pharmceuticals, Inc., US Bioservices is now dispensing TETRABENAZINE. This generic version of XENAZINE®, which launched February 11, 2016, provides a lower-cost alternative to treat chorea (involuntary movements) associated with Huntington’s disease (HD). Continue reading now.
US Bioservices Now Dispensing MS Treatments, PLEGRIDY® and TECFIDERA®
2/8/2016 We are pleased to announce that US Bioservices now has access to Biogen’s limited distribution medications, PLEGRIDY® (peginterferon beta-1a) and TECFIDERA® (dimethyl fumarate). Both drugs are used to treat people with relapsing forms of multiple sclerosis (MS). Continue reading now.
US Bioservices Dispensing Newly Approved ALECENSA®
1/30/2016 The U.S. Food and Drug Administration recently approved Genentech's ALECENSA® (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lunch cancer (NSCLC) whose disease has worsened. Continue reading now.
US Bioservices Expands Access of MyPathpoint Portal to Health Insurers
4/6/2015 National specialty pharmacy provider US Bioservices, a part of AmerisourceBergen, is now offering case managers working for health insurers access toMyPathpoint, a secure HIPAA-compliant web portal that delivers real-time access to patient information. The system is one of the first of its kind to offer case managers real-time access to patients’ specialty pharmacy records in an effort to ensure better experiences and outcomes for members through enhanced care coordination.Continue reading now.